Breast Cancer Prevention Trials Using Retinoids
- 1 January 2003
- journal article
- review article
- Published by Springer Nature in Journal of Mammary Gland Biology and Neoplasia
- Vol. 8 (1) , 19-30
- https://doi.org/10.1023/a:1025779120649
Abstract
Retinoids have been studied as chemopreventive agents in clinical trials. Given their ability to inhibit mammary carcinogenesis in preclinical models. Fenretinide has extensively been investigated...Keywords
This publication has 78 references indexed in Scilit:
- Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia.2002
- Effect of Fenretinide on Ovarian Carcinoma OccurrenceGynecologic Oncology, 2002
- Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.2002
- Aberrant Retinoid Signaling and Breast Cancer: the View From Outside the NucleusJNCI Journal of the National Cancer Institute, 2000
- Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms.1999
- Suppression of cell proliferation and telomerase activity in 4-(hydroxyphenyl)retinamide-treated mammary tumorsCarcinogenesis: Integrative Cancer Research, 1999
- Effects of Fenretinide (4-HPR) on Dark AdaptationArchives of Ophthalmology (1950), 1998
- 4-Hydroxyphenyl Retinamide Is a Highly Selective Activator of Retinoid ReceptorsJournal of Biological Chemistry, 1996
- Chemoprevention of Mammary Carcinogenesis in the Rat: Combined Use of Raloxifene and 9-cis-Retinoic AcidJNCI Journal of the National Cancer Institute, 1996
- Tolerability of the synthetic retinoid fenretinide® (HPR)European Journal of Cancer and Clinical Oncology, 1989